Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prostate cancer vaccine - KAEL-GemVax

Drug Profile

Prostate cancer vaccine - KAEL-GemVax

Alternative Names: ONY-P; ONY-P1; ONY-P2; Onyvax-P

Latest Information Update: 23 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onyvax
  • Developer KAEL-GemVax; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 23 Jun 2015 Phase-II development appears to be ongoing for Prostate cancer
  • 18 Nov 2009 A phase II clinical trial that was taking place at the Mayo Clinic in the US in patients with non-metastatic prostate cancer has been suspended
  • 01 Sep 2009 VaxOnco acquires all intellectual property rights to this prostate cancer vaccine from Onyvax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top